ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals successfully completed a $138 million initial public offering, increasing its cash reserves to $204.2 million as of April 30. The funds are expected to support operations into 2023. Key developments include the first patient dosed in the ORIC-101 Phase 1b trial and promising preclinical data on the CD73 inhibitor ORIC-533. The company also strengthened its leadership team with new appointments. ORIC anticipates crucial data readouts in 2021 and plans to file for an IND for ORIC-533 in the first half of 2021.
Summary not available.
Summary not available.